Leukemia Research
Volume 23, Issue 8 , Pages 701-707, August 1999

The importance of cell size and surface marker analysis in childhood acute myeloblastic leukemia

  • Lale Olcay

      Affiliations

    • Division of Pediatric Hematology, Department of Pediatrics, Hacettepe University, Faculty of Medicine, Ankara, Turkey
  • ,
  • Ulya Ertem

      Affiliations

    • Division of Oncology, Doctor Sami Ulus Children’s Hospital, Ankara, Turkey
  • ,
  • Hamza Okur

      Affiliations

    • Division of Pediatric Hematology, Department of Pediatrics, Hacettepe University, Faculty of Medicine, Ankara, Turkey
  • ,
  • A.Murat Tuncer

      Affiliations

    • Division of Pediatric Hematology, Department of Pediatrics, Hacettepe University, Faculty of Medicine, Ankara, Turkey
    • Corresponding Author InformationCorresponding author. Present address: Institute of Child Health, Hacettepe Children’s Hospital, 06100 Ankara, Turkey. Tel.: +90-312-324-1681; fax: +90-312-324-3284

Received 28 July 1998; accepted 5 February 1999.

Abstract 

In order to evaluate the prognostic significance of cell size and surface marker expression, we evaluated 33 children with newly diagnosed acute myeloblastic leukemia by flow cytometry. We determined: the percentage of small, middle and large cells; large to small cell ratios (LS); large plus middle to small cell ratios (LMS); the percentage of surface markers expressed by each group of cell; the ratios of surface marker percentages expressed by the large blasts to that expressed by small blasts (LS for surface markers); and large plus middle blasts to that by small blasts (LMS for surface markers). For ‘early prognosis’, patients who could and could not achieve remission (n=23 and 10) and for late prognosis, the patients who deceased or relapsed within the first 12 months of the treatment (n=24) and who survived for more than 12 months (n=9) were compared, in two classifications. CD3 percentages of the small cells of alive patients were significantly higher than that of dead or relapsed patients. LMS for CD3 and CD20 and LS for CD20 were higher in dead–relapsed patients than that of alive patients. The total percentage of CD14 was significantly higher in dead–relapsed patients than it was in the alive patients and CD3 was significantly higher in the group of patients who achieved remission than that of the patients who could not achieve remission. It was striking that, expression of CD3, CD7, CD22, CD33, CD14, CD15, CD34 increased or decreased as to cell size, whatever the prognosis. CD10, CD20 and CD13 were expressed on the large cells of the patients who could not achieve remission or died–relapsed. We showed that, the blast cell size, individually does not have any prognostic significance in childhood AML and the prognostic significance of surface markers not only depends on their presence or absence but also on their relative configuration of expression by the blasts with different size.

Keywords: Blast size, Prognosis, Childhood, Acute myeloblastic leukemia

Abbreviations: ALL, acute lymphoblastic leukemia, AML, acute myeloblastic leukemia, LMS, Large plus middle to small cell ratio, LMS for surface markers, the ratio of surface marker percentages expressed by the large plus middle blasts to that by small blasts, LS, large to small cell ratio, LS for surface markers, ratio of surface marker percentages expressed by the large blasts to that by small blasts, MFI, mean fluorescence intensity

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0145-2126(99)00053-3

Leukemia Research
Volume 23, Issue 8 , Pages 701-707, August 1999